Do coagulation abnormalities contribute to sepsis associated organ failure?

Critical Care Medicine

Volumn 34, Issue 6, 2006, Pages 1842-1844

  Abraham, Edward ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Coagulation cascade; Infection; Sepsis

Indexed keywords

ALPHA CHEMOKINE; ANTITHROMBIN; BLOOD CLOTTING FACTOR 7A; CYTOKINE; DROTRECOGIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 2; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

BLOOD CLOTTING DISORDER; CELL INFILTRATION; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; EDITORIAL; HUMAN; INFLAMMATORY DISEASE; LOBAR PNEUMONIA; LUNG INFECTION; LUNG LAVAGE; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPSIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTITHROMBIN III; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; FACTOR VIIA; HUMANS; MICE; PEPTIDE HYDROLASES; PROGNOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOPLASTIN;

EID: 33744552226     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000220051.19432.05     Document Type: Editorial

References (13)

1. Rijneveld AW, Weijer S, Bresser P, et al: Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34:1725-1730
2. Nick JA, Coldren CD, Geraci MW, et al: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104:3878-3875
3. van der Poll T, Levi M, Nick JA, et al: Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171:1125-1128
4. Carr C, Bild GS, Chang AC, et al: Recombinant E. coll-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gram-negative model of septic shock. Circ Shock 1994; 44:126-137
5. Creasey AA, Chang AC, Feigen L, et al: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91:2850-2860
6. Taylor FB Jr, Chang A, Ruf W, et al: Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33:127-134
7. de Jonge E, Dekkers PE, Creasey AA, et al: Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 2001; 183:1815-1818
8. Levi M, de Jonge E, van der Poll T: Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003; 16:43-47
9. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
10. Sturn DH, Kaneider NC, Feistritzer C, et al: Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003; 102:1499-1505
11. Riewald M, Petrovan RJ, Donner A, et al: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296:1880-1882
12. Wurfel MM, Park WY, Radella F, et al: Identification of high and low responders to lipopolysaccharide in normal subjects: An unbiased approach to identify modulators of innate immunity. J Immunol 2005; 175:2570-2578
13. Yang KY, Arcaroli JJ, Abraham E: Early alterations in neutrophil activation are associated with outcome in acute lung injury. Am J Respir Crit Care Med 2003; 167:1567-1574